STING is an important immune-related protein that helps sound the alarm when DNA—such as from viruses or cancer cells—is found where it shouldn’t be. Activation of STING stimulates an immune response, and by activating STING in the tumor environment it may be possible to boost immune responses against cancer. However, because STING’s precise mechanisms remain poorly understood, Dr. Philip Kranzusch seeks to characterize how its structure changes during activation and define the specific gene program required to stimulate immune responses against tumors. The results of these experiments will guide the design of next-generation STING-activating drugs that can be used to enhance immunotherapy’s effectiveness.
Dana-Farber Cancer Institute | All Cancers | 2017
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Meet three promising young scientists changing the face of immuno-oncology: Ryan K. Alexander, Ph.D., of Boston Children’s Hospital; Nelson M. LaMarche, Ph.D., of the Icahn School of Medicine at Mount Sinai; and Christopher B. Medina, Ph.D., of Emory University.
New research, new treatments, and how we’re working toward a future immune to cervical cancer